MedTrace Logo

p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors

NCT01975116 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-08-07

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of azurin-derived cell-penetrating peptide p28 (p28) in treating patients with recurrent or progressive central nervous system tumors. Drugs used in chemotherapy, such as azurin-derived cell-penetrating peptide p28, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Conditions

  • Teratoid Tumor, Atypical
  • Choroid Plexus Neoplasms
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Brainstem Tumors
  • Giant Cell Glioblastoma
  • Glioblastoma
  • Gliosarcoma
  • Medulloblastoma
  • Neuroectodermal Tumor, Primitive

Interventions

DRUG

azurin-derived cell-penetrating peptide p28

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Pediatric Brain Tumor Consortium

    lead NETWORK

Principal Investigators

  • Stewart Goldman · Pediatric Brain Tumor Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01975116 on ClinicalTrials.gov